Biblio
SWI/SNF blockade disrupts PU.1-directed enhancer programs in normal hematopoietic cells and acute myeloid leukemia. Cancer Res. 2023.
SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022.
. Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Adv. 2021.
Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes. Exp Hematol. 2016.
. Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning. Cell Stem Cell. 2019;24(4):511-512.
. Hematologic DNMT3A reduction and high-fat diet synergize to promote weight gain and tissue inflammation. iScience. 2024;27(3):109122.
.